Today, it was announced that Hoau-Yan Wang, a former paid science advisor to Cassava Sciences, Inc. (Nasdaq: SAVA), has been indicted by a federal grand jury for allegedly defrauding the U.S. National Institutes of Health (NIH). Dr. Wang, who was a tenured medical professor at a public university’s medical school, is accused of engaging in illegal behavior to secure approximately $16 million in grants from the NIH between 2017 and 2021. These grants were intended for research related to the early development of Cassava Sciences’ drug candidate and diagnostic test.
Despite his former affiliation with the company, Dr. Wang and his former university have no involvement in the current research and development efforts for simufilam, which is Cassava Sciences’ lead drug candidate for the treatment of Alzheimer’s disease. It is important to note that Dr. Wang’s work under these grants did not involve the Company’s Phase 3 clinical trials of simufilam.
For more information on this matter, please contact Eric Schoen, Chief Financial Officer of Cassava Sciences, at (512) 501-2450 or via email at ESchoen@CassavaSciences.com.
Ally Ewing and Jennifer Kupcho came close to winning the recent Dow Championship, but ultimately…
Posit has unveiled a public preview of their next-generation data science IDE, Positron. The company…
A 33-year-old man was suddenly stricken with cardiac arrest while drinking water. After almost 50…
In July and August of 2024, Israel’s main airport, Ben Gurion Airport, is expected to…
Ticky, a 3-year-old spider monkey, has been bringing joy to both her owner and people…
A violent storm tore through Croatia, wreaking havoc on the roads. The footage from the…